Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

MiMedx Group, Inc. (MDXG)

3.14   0.02 (0.64%) 11-28 09:43
Open: 3.2 Pre. Close: 3.12
High: 3.181 Low: 3.08
Volume: 12,047 Market Cap: 357(M)

Technical analysis

as of: 2022-11-28 9:20:09 AM
Overall:       
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 4.08     One year: 4.77
Support: Support1: 2.93    Support2: 2.58
Resistance: Resistance1: 3.5    Resistance2: 4.08
Pivot: 3.15
Moving Average: MA(5): 3.13     MA(20): 3.09
MA(100): 3.32     MA(250): 4.13
MACD: MACD(12,26): 0     Signal(9): 0
Stochastic oscillator: %K(14,3): 49.8     %D(3): 50
RSI: RSI(14): 50.9
52-week: High: 7.63  Low: 2.58
Average Vol(K): 3-Month: 524 (K)  10-Days: 414 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ MDXG ] has closed above bottom band by 43.8%. Bollinger Bands are 22.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 3.2 - 3.22 3.22 - 3.24
Low: 3.01 - 3.03 3.03 - 3.05
Close: 3.09 - 3.12 3.12 - 3.15

Company Description

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a semi-permeable protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications; and AMNIOBURN a semi-permeable protective barrier allograft used in the treatment of partial-thickness and full-thickness burns, as well as lead product includes mdHACM, a micronized form of AMNIOFIX, supplied in powder form. The company's products have applications primarily in the areas of wound care, burn, surgical, and non-operative sports medicine sectors of healthcare. It also sells allografts for dental applications on an original equipment manufacturer basis. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. is headquartered in Marietta, Georgia.

Headline News

Tue, 15 Nov 2022
Chronic Obstructive Pulmonary Disease (COPD) Market Expected to Reach $25 Billion By 2027 - StreetInsider.com

Thu, 03 Nov 2022
MDXG: KOA Trial Launch Around the Corner - Yahoo Finance

Wed, 02 Nov 2022
MiMedx: Q3 Earnings Snapshot - Plainview Daily Herald

Wed, 02 Nov 2022
MiMedx Group, Inc. (MDXG) Q3 2022 Earnings Call Transcript - Seeking Alpha

Wed, 26 Oct 2022
On Wednesday, MiMedx Group (MDXG) is expected to report earnings. - Best Stocks

Thu, 13 Oct 2022
MiMedx Group, Inc. (NASDAQ:MDXG) insiders who sold US$1.7m worth of stock earlier this year are probably glad they did so as market cap slides to US$306m - Simply Wall St

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 114 (M)
Shares Float 80 (M)
% Held by Insiders 4.1 (%)
% Held by Institutions 63.5 (%)
Shares Short 3,660 (K)
Shares Short P.Month 4,040 (K)

Stock Financials

EPS -0.18
EPS Est Next Qtl 0.09
EPS Est This Year 0.31
EPS Est Next Year 0.4
Book Value (p.s.) -0.18
Profit Margin (%) -10.6
Operating Margin (%) -8.7
Return on Assets (ttm) -8.1
Return on Equity (ttm) -34.6
Qtrly Rev. Growth 7.3
Gross Profit (p.s.) 1.89
Sales Per Share 2.29
EBITDA (p.s.) -0.17
Qtrly Earnings Growth 0
Operating Cash Flow -16 (M)
Levered Free Cash Flow -7 (M)

Stock Valuations

PE Ratio -18.25
PEG Ratio -0.8
Price to Book value -18.36
Price to Sales 1.35
Price to Cash Flow -22.89

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.